Clinical Trials Logo

Filter by:
NCT ID: NCT00308464 Terminated - Clinical trials for Growth Hormone Deficiency

A Study To Evaluate The Dose Response And Safety Of PHA-794428 In Adults With Growth Hormone Deficiency

Start date: July 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore the safety, toleration and dose response of PHA-794428 after multiple weekly injections in male and female growth hormone deficient patients.

NCT ID: NCT00307775 Terminated - Fecal Incontinence Clinical Trials

Vaginal Estrogen for the Treatment of Faecal Incontinence in Women

Start date: March 2006
Phase: N/A
Study type: Interventional

This study will address the following questions: - Does the use of oestrogen inserted vaginally with an applicator, help with the symptoms of faecal (bowel) incontinence in women who are past the age of menopause? - Do women find it easy to use? - Is the treatment safe for the womb lining? - Is there any systemic absorption of the treatment?

NCT ID: NCT00307645 Terminated - Clinical trials for Renal Limited Vasculitis

IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis

Start date: May 2003
Phase: Phase 3
Study type: Interventional

The aim of IMPROVE is to define the optimal maintenance therapy for ANCA-associated vasculitides (AASV) by comparing the AZA (standard regimen) with MMF in terms of efficacy, i.e. in preventing relapses. HYPOTHESIS : MMF might be more effective than azathioprine as maintenance drug in AASV patients, reducing by 50% relapse rate, with a same frequency of adverse effects

NCT ID: NCT00306150 Terminated - Clinical trials for Blood Loss, Surgical

Efficacy and Safety of Aprotinin on Transfusion Requirements in Patients Undergoing Radical or Total Cystectomy

Start date: December 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess if aprotinin (BAYA0128), given intravenously during your surgery, is safe and can help reduce the need for a blood transfusion during bladder surgery.

NCT ID: NCT00306137 Terminated - Clinical trials for Blood Loss, Surgical

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer

Start date: December 2005
Phase: Phase 3
Study type: Interventional

Study to Investigate the Effect of Aprotinin of Transfusion Requirements in Patients Undergoing Surgical Procedures for Lung or Esophageal Cancer.

NCT ID: NCT00304252 Terminated - Crohn's Disease Clinical Trials

Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease

Start date: November 2001
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of interferon beta-1a in maintaining remission in patients with Crohn's disease.

NCT ID: NCT00300885 Terminated - Clinical trials for Carcinoma, Non-Small Cell Lung

A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Start date: February 2006
Phase: Phase 3
Study type: Interventional

A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.

NCT ID: NCT00300040 Terminated - Clinical trials for Peripheral Vascular Disease

Safety/Feasibility Study of HBOC-201 in Amputation at/Below Knee From Critical Lower Limb Ischemia

Start date: May 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and feasibility of HBOC-201 in increasing adequate wound healing in patients with severe peripheral vascular disease who are undergoing lower limb amputation. The hypothesis is that HBOC-201 will pass through the partially occluded lesions in the peripheral arteries in the lower extremity and promote the wound healing process by delivering oxygen to the oxygen deprived tissues. This will reduce the incidence of lower limb wound complications at 60 days post-surgery and may reduce the incidence of a second amputation.

NCT ID: NCT00297232 Terminated - Clinical trials for Relapsing-Remitting Multiple Sclerosis

Natalizumab (Tysabri) Re-Initiation of Dosing

STRATA
Start date: March 2006
Phase: Phase 3
Study type: Interventional

The primary objectives for the initial treatment period of this study are to further evaluate the safety of natalizumab monotherapy by evaluating the risk of hypersensitivity reactions and immunogenicity following re-exposure to natalizumab and confirming the safety of switching from interferon (IFN), glatiramer acetate, or other multiple sclerosis (MS) therapies to natalizumab. The primary objective for the long-term treatment period of this study is to evaluate the long-term impact of natalizumab monotherapy on the progression of disability measured by Expanded Disability Status Scale (EDSS) changes over time.

NCT ID: NCT00297193 Terminated - Crohn Disease Clinical Trials

ASTIC Autologous Stem Cell Transplantation for Crohn's Disease

Start date: June 2006
Phase: Phase 3
Study type: Interventional

Transplant study for patients with relapsing Crohn's disease demonstrating clear intolerance or toxicity to conventional treatment. The purpose of this study is to determine whether there is a potential clinical benefit of hematopoietic stem cell mobilisation followed by high dose immuno-ablation and autologous stem cell transplantation versus hematopoietic stem cell mobilisation only followed by best clinical practice.